SILVER SPRING, Md., March 9, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its new website is now live and can be viewed at www.PharmaCyteBiotech.com. PharmaCyte Biotech’s new website
Read more →SILVER SPRING, Md., Feb. 24, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), announced today that Dr. Matthius Lohr, Chairman of its Scientific Advisory Board, together with his colleagues Dr. Verbeke, Dr. Severin Karlsson
Read more →SILVER SPRING, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low
Read more →SILVER SPRING, Md., Feb. 13, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today reported that its partner, the University of Technology Sydney (UTS), has published a review article on cell and gene therapies
Read more →SILVER SPRING, Md., Feb. 2, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R), today reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment
Read more →SILVER SPRING, Md., Feb. 2, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R), today reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment of diabetes has commenced
Read more →SILVER SPRING, Md., Jan. 29, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R), announced today that its partner, Austrianova, has officially opened its new facilities at Synapse within Biopolis in Singapore. Biopolis is
Read more →SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R), today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of
Read more →SILVER SPRING, MD, January 15, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an
Read more →Company Trading Under New Ticker Symbol PMCB SILVER SPRING, MD, January 8, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today announced that the Company is trading under its new ticker symbol
Read more →